Sondakika! Phase 2/3 of the COVID-19 antibody treatment studies have begun

  It was announced that if the first results to be provided before the end of 2020 are positive, early access to antibody therapy in the first half of 2021 will be possible.

  GSK and Vir Biotechnology announced that the dose has been administered to the first patient as part of the Phase 2/3 study for early treatment of COVID-19 in patients at high risk of hospitalization.

  The PHASE 2/3 study, which included approximately 1,300 symptomatic early-infection patients worldwide, was conducted to assess whether a single dose of monoclonal antibody (VIR-7831) would prevent hospitalization due to COVID-19.  In the study, which aims to obtain the first results before the end of this year, if the results are successful, it will be possible to reach antibody therapy as early as the first half of 2021.

  Head of Research and Development at GSK and Scientific Officer Dr.  “Monoclonal antibodies against the SARS-CoV-2 virus can provide an effective and immediate immune response to COVID-19 without waiting for our bodies to produce their own antibodies,” Hal Barron said in a statement.  I think this is especially important in the absence of an effective vaccine.  This study will assess the ability of VIR-7831 to prevent high-risk individuals from progressing to severe disease.  In future studies, we will also test the rate at which the antibody can prevent infection and reduce disease severity in patients at high risk. “

  PhD CEO Ver.  “It’s very important for both patients and the community to treat patients with the onset of COVID-19 in a way that prevents them from getting worse,” said George Scangos. “Hospital systems around the world have failed, with new infections continuing to strain currently limited resources. This study is designed to show whether  VIR-7831 was able to significantly reduce the need for hospitalization in the elderly or high-risk individuals with chronic illnesses.

Hibya Haber Ajansı

Kamu Söz / Son Dakika Haberler

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir